BHVN FINAL DEADLINE: ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Biohaven Ltd. Investors with Losses in Excess of $100K to Secure Counsel Before Important September 12 Deadline in Securities Class Action – BHVN

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Biohaven Ltd. securities during the specified Class Period of the upcoming lead plaintiff deadline on September 12, 2025, for a class action lawsuit [1][2]. Group 1: Class Action Details - Investors who bought Biohaven securities between March 24, 2023, and May 14, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by the specified deadline [2]. - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [3]. Group 2: Case Allegations - The lawsuit alleges that during the Class Period, Biohaven made false and misleading statements regarding the regulatory prospects of its drug, troriluzole, for treating spinocerebellar ataxia (SCA) and the efficacy of BHV-7000 for bipolar disorder [4]. - It is claimed that the overstated regulatory prospects and clinical data could significantly negatively impact Biohaven's business and financial condition once revealed [4]. - The lawsuit asserts that the public statements made by the defendants were materially false and misleading throughout the Class Period, leading to investor damages when the truth emerged [4].